Description

Indication & Scope

BASEN® is a prescription alpha-glucosidase inhibitor indicated as an adjunct to diet and exercise to improve postprandial glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with other oral antidiabetic agents or insulin when postprandial blood glucose remains inadequately controlled. It is not indicated for the treatment of type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma.

Mechanism: Voglibose competitively inhibits intestinal alpha-glucosidase enzymes, delaying the digestion and absorption of carbohydrates and reducing postprandial blood glucose excursions.
Drug Class: Alpha-glucosidase inhibitor.
Clinical Use: Improvement of postprandial glycemic control in adults with type 2 diabetes mellitus as monotherapy or combination therapy.

Specification

Generic Name	Voglibose Tablets
Brand Name	BASEN®
Ingredient	Voglibose
Dosage Form	Tablet
Package	0.2 mg/tablet, 30 tablets/carton (10 tablets × 3 blisters)
Conditions Treated	Type 2 diabetes mellitus with postprandial hyperglycemia
Taboos	Hypersensitivity to voglibose or any component of the product; diabetic ketoacidosis; diabetic coma or pre-coma; severe infection, major surgery, or severe trauma requiring insulin therapy
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store in a tightly closed container at room temperature, protected from moisture and light.
Manufacturer	Tianjin Takeda Pharmaceuticals Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H20010308
Approval Date	April 24, 2024
Shelf Life	60 months

How to use ?

Recommended Dose: The recommended dose is 0.2 mg three times daily before meals. If necessary, the dose may be increased to 0.3 mg three times daily according to clinical response.

Time: Take immediately before each main meal.

Instructions for use: Swallow the tablet with water before meals. If a meal is skipped, skip the corresponding dose. Do not take the medicine after meals to make up for a missed dose.

Interaction: The risk of hypoglycemia increases when used with insulin, sulfonylureas, or meglitinides. Digestive enzyme preparations may reduce the therapeutic effect of voglibose.

Side effects: Common adverse reactions include flatulence, abdominal distension, diarrhea, abdominal discomfort, constipation, and nausea. When combined with other antidiabetic agents, hypoglycemia may occur. Rare but serious adverse reactions include intestinal obstruction, severe hepatic dysfunction, jaundice, and hypersensitivity reactions.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support